Aldeyra Therapeutics, Inc.ALDX

Market cap

$297.08M

P/E ratio

	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Cash and cash equivalents	-	-	-	-	3	16	53	105	144	143	55
Cash Equivalent Reverse Repurchase Agreement	-	-	-	-	44	28	25	125	-	-	-
Marketable securities	-	-	-	-	-	29	-	-	30	-	47
Prepaid expenses and other current assets	232,568	497,552	218,682	1	1	2	5	3	7	5	3
Total current assets	9	28	25	44	95	75	83	233	181	148	104
Deferred offering costs	-	-	-	-	-	-	-	-	-	-	267,261
Fixed assets, net	12,993	80,334	56,352	43,262	235,225	148,449	59,925	32,487	19,279	5,764	-
Right-of-use assets	-	-	-	-	-	201,007	233,310	351,863	249,265	1	266,955
Total assets	9	28	25	44	95	76	83	233	181	148	105
Accounts payable	341,294	851,160	275,441	1	3	808,302	381,638	1	133,625	1	180,453
Accrued expenses	908,724	1	2	2	5	12	8	11	14	6	12
Current portion of debt	77,546	77,546	77,546	116,319	-	-	-	-	911,763	15	31,372
Operating lease liabilities	-	-	-	-	-	226,328	233,310	229,607	249,265	239,183	271,631
Deferred Revenue, Current	-	-	-	-	-	-	-	-	-	-	6
Total current liabilities	1	2	2	3	8	13	12	12	15	22	19
Deferred Long-Term Liability Charges	-	-	-	-	-	-	-	-	-	6	-
Operating lease liabilities, long-term	-	-	-	-	-	-	-	125,232	-	271,631	-
Long-term debt, net of current portion	1	1	1	1	-	15	11	16	15	-	15
Total liabilities	3	3	4	5	8	27	24	27	30	29	34
Common Stock, Value, Issued	-	9,713	12,576	19,138	26,244	28,657	38,667	58,081	58,560	59,196	59,648
Additional paid-in capital	53	83	99	139	225	247	296	500	508	514	521
Accumulated other comprehensive income	-	-8,361	129	-17,831	-9,224	5,866	-	-	-103,938	-	37,442
Accumulated deficit	-46,511,597	-58,601,884	-77,301,334	-99,641,923	-138,535,168	-199,361,999	-236,915,728	-294,692,002	-356,716,638	-394,259,148	-450,110,592
Total stockholders’ equity	6	25	22	40	87	48	60	206	151	120	71
Total liabilities and stockholders’ equity	9	28	25	44	95	76	83	233	181	148	105